247 results on '"Gifford, Alex H."'
Search Results
2. Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial
3. Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study
4. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis
5. Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis: The Prospective Study of Peripherally Inserted Venous Catheters in People With Cystic Fibrosis Study
6. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
7. Update on Clinical Outcomes of Highly Effective Modulator Therapy
8. Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators
9. Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs
10. Inflammation in CF: Key Characteristics and Therapeutic Discovery
11. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.
12. Formative evaluation of a dashboard to support coproduction of healthcare services in cystic fibrosis
13. Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy
14. A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends
15. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study
16. The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial
17. Clinical Utility of Prognostic Scoring Systems in Patients with Hematological Malignancies Who Require Mechanical Ventilation
18. Outcome of Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients
19. Complications of long and intermediate term venous catheters in cystic fibrosis patients: A multicenter study
20. Psychological Factors as Determinants of Noninvasive Continuous Positive Airway Pressure Response: Key Practical Aspects and Topics
21. Quality of Life during Long-Term Mechanical Ventilation in Hypercapnic Respiratory Failure: Main Determinants and Evidence
22. Noninvasive Open Ventilation (NIOV™) Therapy: Clinical Implications
23. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
24. Prospective Use of Descriptors of Dyspnea to Diagnose Common Respiratory Diseases
25. Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
26. Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease
27. Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis
28. Effect of Increased Blood Levels of β-Endorphin on Perception of Breathlessness
29. THE PLEURAL EFFUSION THAT NEVER WAS: PERICARDIAL EFFUSION CAUSING LUNG COLLAPSE
30. Room to breathe: The promise of a more flexible cystic fibrosis care model.
31. Mechanism of Greater Oxygen Desaturation During Walking Compared With Cycling in Patients With COPD
32. Respiratory Function in an Obese Patient With Sleep-Disordered Breathing
33. Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry
34. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
35. Calprotectin-Mediated Zinc Chelation Inhibits Pseudomonas aeruginosa Protease Activity in Cystic Fibrosis Sputum
36. Reducing treatment burden in the era of CFTR modulators – Authors' reply
37. Chronic Dyspnea
38. Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosis
39. Contributors to Second Edition
40. Dyspnea
41. Mitwirkende Autoren
42. Contributors
43. CONTRIBUTORS
44. Serum and Sputum Iron Trends Distinguigh Responders and Non-Responders to Treatment of Cystic Fibrosis Pulmonary Exacerbation
45. An Unusual Cause of Endobronchial Obstruction
46. Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence?
47. Availability of Zinc Impacts Interactions between Streptococcus sanguinis and Pseudomonas aeruginosa in Coculture
48. Does Ivacaftor Taken Twice a Day Keep the Pseudomonas Away?
49. Perspectives on anemia and iron deficiency from the cystic fibrosis care community
50. CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.